Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 5 December 2006
Vol. 2006, Issue 364, p. tw407
[DOI: 10.1126/stke.3642006tw407]


Pain A Painful Endogenous Opioid

Nancy R. Gough

Science's STKE, AAAS, Washington, DC 20005, USA

Dynorphin A1-17 is derived from proteolytic processing of prodynorphin and has high affinity for µ, {delta}, and {kappa} opioid receptors. However, increased amounts of dynorphin A are found in models of chronic pain, and antibodies against dynorphin A alleviate, rather than potentiate, pain. Lai et al. show that a fragment of dynorphin A that has low affinity for the opioid receptors (dynorphin A2-13) stimulated a transient increase in intracellular calcium concentration in cultured embryonic dorsal root ganglion (DRG) cells and in F-11 cells, a neuroblastoma-DRG hybridoma. The increase in intracellular calcium was blocked by selective inhibition of L-type or P/Q-type voltage-sensitive calcium channels. A bradykinin B2 antagonist blocked the dynorphin-induced increase in intracellular calcium, and transfection of either the bradykinin B2 or B1 receptor reconstituted dynorphin A2-13 responsiveness in cells that had spontaneously lost the ability to respond to dynorphin A. Dynorphin A2-13 or dynorphin A1-17 competed for binding to B1 or B2 receptors, suggesting that dynorphin is acting as an agonist at the bradykinin receptors. In rats, intrathecal injection of dynorphin A2-13 caused enhanced sensitivity to touch and heat, and these effects were reversed by injection of a B2 receptor antagonist. Furthermore, knockout mice lacking B2 receptors did not show hypersensitive responses in response to dynorphin A2-13 injection. Finally, in a rat model of neuropathic pain, B2 receptor and prodynorphin transcript abundance were increased in the DRG of rats as early as day 2 after nerve injury, and treatment with a B2 antagonist after nerve injury prevented hypersensitivity responses. As discussed by Altier and Zamponi, it appears that under conditions of chronic pain, enhanced production of dynorphin in the spinal cord produces a hyperalgesia response instead of an analgesic response through the ability of dynorphin to activate spinal bradykinin receptors.

J. Lai, M.-C. Luo, Q. Chen, S. Ma, L. R. Gardell, M. H. Ossipov, F. Porreca, Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat. Neurosci. 9, 1534-1540 (2006). [PubMed]

C. Altier, G. W. Zamponi, Opioid, cheating on its receptors, exacerbates pain. Nat. Neurosci. 9, 1465-1467 (2006). [PubMed]

Citation: N. R. Gough, A Painful Endogenous Opioid. Sci. STKE 2006, tw407 (2006).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882